⚡

Tirzepatide

Dual-Action Protocol

5mg × 10 vials — Weight Loss

10 vials — 12 months supply

Overtaking semaglutide as the preferred option due to superior weight loss data. r/Tirzepatide is extremely active.

$210

= $0.58/day

Cart

What it does

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Unlike Semaglutide which only targets GLP-1, Tirzepatide activates both GIP and GLP-1 receptors. GIP enhances insulin secretion and may improve fat metabolism, while GLP-1 reduces appetite and slows digestion.

This dual-pathway approach produces superior metabolic outcomes compared to single-agonist compounds, with clinical data showing approximately 60% greater weight reduction than semaglutide alone.

Dosage & Protocol

Subcutaneous injection, once weekly. Titration: 2.5mg (weeks 1-4), 5mg (weeks 5-8), 7.5mg (weeks 9-12), 10mg (weeks 13-16), 12.5mg (weeks 17-20), 15mg (week 21+). 10 vials provides approximately 12 months at standard dosing.

Duration

12 months

Format

10-vial protocol box

Purity

99%+ (CoA verified)

Delivery

7-14 days worldwide

What to expect

Week 1-4: Mild appetite reduction during titration. Minimal weight loss (1-3 lbs). GI effects milder than semaglutide at equivalent efficacy.

Week 4-8: Significant appetite suppression at 5-7.5mg. Weight loss accelerates (1-2.5 lbs/week).

Week 8-16: Strong consistent weight loss. Dramatic reduction in food noise and cravings.

Week 16-72: Peak weight loss. SURMOUNT-1 showed 22.5% mean weight loss at 15mg by 72 weeks. Some users achieve 25%+.

Who it's for

Researchers looking for enhanced metabolic outcomes beyond single-agonist GLP-1 compounds

Those studying dual-pathway activation and its effects on body composition

Anyone who has plateaued on semaglutide and wants to explore the next generation

Researchers comparing single vs dual agonist efficacy

📖

Read the full Tirzepatide profile in the Peptide Bible

Dosing protocols, stacking guides, safety data, and research references.

Browse Bible

The research

📄

StatPearls: Comprehensive clinical pharmacology of tirzepatide(NBK585056)

📄

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight 2020)(10.1172/jci.insight.140532)

Safety notes

⚠️Common side effects: Nausea, diarrhea, vomiting, constipation — potentially milder than semaglutide at equivalent efficacy due to biased agonism.

⚠️Serious but rare: Pancreatitis, gallbladder events, thyroid C-cell tumors (rodent data, boxed warning).

⚠️Muscle loss concern: Even more important than semaglutide due to greater total weight loss. Resistance training critical.

Pairs well with

L-Carnitine

Supports fat oxidation during accelerated weight loss

BPC-157

GI support if nausea occurs

Complete Your Protocol

Triple-Action Protocol

$280$0.77/day

💧

Bacteriostatic Water

Essential for Reconstitution

$20Required

Frequently Asked Questions

Start My Dual-Action Protocol

5mg × 10 vials — 12 months supply — $210 — $0.58/day

Includes Peptide Bible, CoA certificate, and Telegram support